非酒精性脂肪性肝病的饮食治疗

doi:10.3969/j.issn.1672-5069.2014.05.002

Abstract

Cao Haixia, Fan Jiangao. Dietary management of patients with nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(5): 452-455.

[1] Fan JG. Epidemiology of alcohol and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol,2013,28（Suppl 1）:11-17.
[2] Yilmaz Y,Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis,2014,18:19-31.
[3] 陈东风, 熊吉. 非酒精性脂肪性肝炎:现状与未来. 实用肝脏病杂志,2013,16（6）:481-482.
[4] Angulo P. Nonalcoholic fatty liver disease. N Engl J Med, 2002,346:1221-1231.
[5] Machado M,Marques-Vidal P,Cortez-Pinto H. Hepatic histology in obese patientsundergoing bariatric surgery. J Hepatol,2006,45:600-606.
[6] Cao HX,Fan JG. Editorial:Fatty liver disease:a growing public health problem worldwide. J Dig Dis,2011,12:1-2.
[7] 沈峰,丁晓东,范建高. 美国非酒精性脂肪性肝病诊疗指南简介. 实用肝脏病杂志,2012,15（4）:362-363.
[8] Asrih M,Jornayvaz FR. Diets and nonalcoholic fatty liver disease:The good and the bad. Clin Nutr,2013 Nov 8. pii: S0261-5614（13）00304-X. doi:10.1016/j.clnu.2013.11.003. [Epub ahead of print]
[9] Mouzaki M,Allard JP.The role of nutrients in the development, progression,andtreatment of nonalcoholic fatty liver disease. J Clin Gastroenterol,2012,46:457-467.
[10] McCarthy EM,Rinella ME. The role of diet and nutrient composition in nonalcoholic fatty liver disease. J Acad Nutr Diet,2012,112:401-409.
[11] de Wit NJ,Afman LA,Mensink M,et al. Phenotyping the effect of diet onnon-alcoholic fatty liver disease. J Hepatol,2012,57:1370-1373.
[12] Sacks FM,Bray GA,Carey VJ,et al. Comparison of weight-loss diets with different compositions of fat,protein,and carbohydrates. N Engl J Med,2009,360:859-873.
[13] Yasutake K,Kohjima M,Nakashima M,et al. Nutrition therapy for liver diseases based on the status of nutritional intake. Gastroenterol Res Pract,2012,2012:859697.
[14] 范建高,曾民德. 脂肪性肝病. 2版.北京：人民卫生出版社, 2013:459-467.
[15] Moyer VA.U.S. Preventive Services Task Force. Screening for and managementof obesity in adults:U.S. Preventive Services Task Force recommendation statement. Ann Intern Med,2012,157:373-378.
[16] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 中华肝脏病杂志,2010,18:153-166.
[17] Thoma C,Day CP,Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults:a systematic review. J Hepatol,2012,56:255-266.
[18] Musso G,Cassader M,Rosina F,et al. Impact of current treatments on liver disease,glucose metabolism and cardiovascular risk in non-alcoholic fattyliver disease（NAFLD）:a systematic review and meta-analysis of randomizedtrials. Diabetologia,2012,55:885-904.
[19] Nomura K,Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem,2012,23:203-208.
[20] Colak Y,Tuncer I,Senates E,et al. Nonalcoholic fatty liver disease:anutritional approach. Metab Syndr Relat Disord,2012,10:161-166.
[21] Jun DW. The role of diet in non-alcoholic fatty liver disease. Korean J Gastroenterol,2013,61:243-251.
[22] Utzschneider KM,Bayer-Carter JL,Arbuckle MD,et al. Beneficial effect of weight-stable,low-fat/low-saturated fat/low-glycaemicindex diet to reduce liver fat in older subjects. Br J Nutr,2013,109:1096-1104.
[23] Parker HM,Johnson NA,Burdon CA,et al. Omega-3 supplementation and non-alcoholic fatty liver disease:a systematic review and meta-analysis. J Hepatol,2012,56:944-951.
[24] Bortolotti M,Kreis R,Debard C,et al. High protein intake reduces intrahepatocellular lipid deposition in humans. Am J Clin Nutr,2009,90:1002-1010.
[25] Tovar AR,Torres N. The role of dietary protein on lipotoxicity.Biochim Biophys Acta,2010,1801:367-371.
[26] Corbin KD,Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol,2012,28:159-165.
[27] Masterjohn C,Bruno RS. Therapeutic potential of green tea in nonalcoholic fatty liver disease. Nutr Rev,2012,70:41-56.
[28] Birerdinc A,Stepanova M,Pawloski L,et al. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther,2012,35:76-82.
[29] Dunn W,Sanyal AJ,Brunt EM,et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease （NAFLD）. J Hepatol,2012,57:384-391.
[30] Pacana T,Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care,2012,15:641-648.
[31] Eslamparast T,Poustchi H,Zamani F,et al. Synbiotic supplementation in nonalcoholic fatty liver disease:a randomized, double-blind,placebo-controlled pilot study. Am J Clin Nutr,2014 Jan 8 [Epub ahead of print].
[32] 曹毅, 范建高. 肠道微生态制剂对非酒精性脂肪性肝病的防治作用. 中华医学杂志,2013,93:3235-3237.
[33] 赵欢, 赵彩彦. 肠道菌群失调在慢性肝病发病中的作用研究进展. 实用肝脏病杂志,2014,17（1）:106-108.
[34] Assy N. Nutritional recommendations for patients with non-alcoholicfatty liver diseases. World J Gastroenterol,2011,17:3375-3376.
[35] 茅益民, 曾民德. 加强非酒精性脂肪性肝病的临床和转化医学研究. 实用肝脏病杂志,2012,15（4）:273-275.

Dietary management of patients with nonalcoholic fatty liver diseases

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[2]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[3]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[4]	. [J]. Journal of Practical Hepatology, 2019, 22(5): 624-635.
[5]	Dai Qingyun, Wang Rundong, Jia Weidong. Prediction of early tumor recurrence by predictive nutritional index in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 561-564.
[6]	Gao Zhiliang, Zhu Xiang. How to achieve the clinical cure of hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 305-308.
[7]	Wang Xiaoxiao, Chen Xinyue. Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 309-312.
[8]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[9]	Wang Haifang, Yang Dawei, Jia Bei. Impact of nutrition support and medusa administration on liver function, erythrocyte and platelet parameters in patients with alcoholic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 381-384.
[10]	Liu Liwei, Zhao Xinyan. Clinicopathological features of drug-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 160-163.
[11]	Guideline for diagnosis, treatment of liver failure. [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 164-171.
[12]	Zhao Xiaofei, Lin Dongdong, Li Ning, Zang Yunjin, Guo Qingliang, Wu Juanshan. Application of warfarin in dealing with portal vein thrombosis in patients with liver cirrhosis after splenectomy and devascularization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 240-243.
[13]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[14]	Yusup Tursun, Zhao Yanxia.. Establishment of low-dose diethylnitrosamine-induced liver fibrosis model in rats [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 33-36.
[15]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.